Gene Therapy Clinical Trials
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health.
Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Stanford is currently accepting patients for this trial.
Eligibility
Inclusion Criteria:
- Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or
urethra.
- Locally advanced unresectable or metastatic stage disease
- Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned
slides, see laboratory manual for details) available for HER2 testing.
- At least 1 prior line of systemic therapy for locally advanced unresectable or
metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing
chemotherapy.
- Initiation of anticancer therapy for UC after prior progression on platinum-based
therapy with or without maintenance avelumab between 01 January 2019 and 12 months
before the start of data collection
- Radiographically documented and measurable disease progression immediately before
index date
Exclusion Criteria:
- Any concurrent malignant neoplasm requiring systemic therapy during the study window
- Enrollment in a therapeutic clinical trial and received non-standard of care treatment
within 1 year prior to the index date
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mohsin Rangwala
mrang@stanford.edu
I'm interested